Cabaletta Bio, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. The filing covers the three months ended March 31, 2022, and was filed May 12, 2022. The company has no commercial products and has not generated product revenue.
The lead program, DSG3-CAART, was being evaluated in the Phase 1 DesCAARTes trial for mucosal pemphigus vulgaris. The MuSK-CAART IND became effective in January 2022, and the company planned to initiate the MusCAARTes Phase 1 trial in 2022. Additional programs included DSG3/1-CAART, FVIII-CAART and PLA2R-CAART.
Financial condition and key metrics
| Metric | Three months ended March 31, 2022 | Three months ended March 31, 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $9.2 million | $6.6 million | Up $2.6 million |
| General and administrative expense | $3.8 million | $3.2 million | Up $0.7 million |
| Total operating expenses | $13.0 million | $9.7 million | Up $3.3 million |
| Net loss | $12.9 million | $9.7 million | Loss increased $3.2 million |
| Net loss per share | $0.45 | $0.41 | Loss per share increased |
| Net cash used in operating activities | $12.8 million | $8.7 million | Use increased $4.1 million |
Gross profit and operating margins are not meaningful because the company has no revenue and operates entirely at a loss. Comprehensive loss was $13.1 million in Q1 2022, including a $0.2 million unrealized loss on available-for-sale investments.
As of March 31, 2022, cash and cash equivalents were $59.6 million and short-term investments were $49.7 million, for total cash, cash equivalents and investments of $109.2 million. Total assets were $113.7 million, current liabilities were $6.9 million and stockholders’ equity was $106.7 million. The filing reports no debt or credit facility.
Operating cash use was partly offset by $1.8 million of stock-based compensation and other non-cash adjustments. Investing cash use of $49.9 million primarily reflected purchases of short-term U.S. government securities. Financing cash flow was $0.1 million from stock-option exercises. Cash and cash equivalents declined from $122.2 million at year-end 2021 to $59.6 million, principally because funds were moved into short-term investments.
Material changes versus the prior comparable period
- Research and development spending increased 40%, primarily from higher personnel costs, clinical trial costs, manufacturing costs and sponsored research activity.
- Clinical trial costs increased by approximately $0.8 million, primarily for the DesCAARTes trial.
- Manufacturing costs increased by approximately $0.5 million, reflecting cell-processing capabilities and related activities.
- Personnel-related research and development costs increased by approximately $1.1 million as headcount expanded.
- General and administrative expense increased approximately $0.6 million because of higher personnel and administrative costs.
- The company invested $49.8 million in short-term investments during the quarter; this substantially explains the decrease in cash and cash equivalents and does not represent equivalent operating cash consumption.
- Stock-based compensation increased to $1.8 million from $1.3 million. Unrecognized compensation cost was $17.2 million at March 31, 2022.
- The company amended its Philadelphia office lease and added expanded laboratory space. Future minimum operating lease payments totaled $10.5 million as of March 31, 2022.
Guidance, outlook, commentary and risks
Management stated that cash and cash equivalents as of March 31, 2022 were expected to fund projected operations for at least 12 months after the filing date. Based on its current operating plan, management separately estimated that cash, cash equivalents and investments would fund operations through the third quarter of 2023. These estimates depend on assumptions that may prove incorrect, and additional financing will be required to advance clinical development and fund operations.
The company expects research and development and general and administrative expenses to increase for the foreseeable future. It had no committed credit facility and expected to seek additional funding through equity offerings, debt financing, collaborations, licenses or other sources. Additional equity financing could dilute existing stockholders; debt financing could impose restrictive covenants.
For DSG3-CAART, the company reported no dose-limiting toxicities in the first four cohorts during the applicable 28-day post-infusion periods. However, no clear evidence of biologic activity was observed in the first two low-dose cohorts. The company planned to advance a higher-dose fifth cohort and expected additional clinical and translational data during 2022, subject to enrollment, safety and manufacturing conditions.
- The company remains heavily dependent on the University of Pennsylvania and affiliated entities for research, development, manufacturing and technology transfer.
- Manufacturing is complex, patient-specific and not yet validated for commercial-scale production. Delays in technology transfer, lentiviral-vector supply or contract manufacturing could delay trials.
- Clinical results are early and may not predict later-stage safety or efficacy. Potential risks include cytokine release syndrome, neurotoxicity, off-target activity, inadequate persistence and other adverse events.
- COVID-19 could affect patient enrollment, clinical-site operations, suppliers, manufacturing capacity, regulatory timelines and access to capital, although the company stated that its financial results had not been significantly affected through the filing date.
- The company faces substantial regulatory uncertainty because CAAR T-cell therapies for autoimmune disease are novel and have not previously been approved in the United States or European Union.
- A purported stockholder filed a putative securities class action on February 28, 2022 concerning alleged misstatements and omissions related to the DesCAARTes trial, clinical data, efficacy and commercial prospects. The company intends to defend the case; no loss was accrued because the outcome was not probable or reasonably estimable.
- The company’s principal intellectual-property rights are licensed from Penn and CHOP. The license includes potential milestone payments of approximately $21.0 million in aggregate, low-single-digit royalties on product sales and sublicense-income sharing, although no amounts were due under the license at March 31, 2022.
Most important facts for an investor to verify
- Whether subsequent DesCAARTes data demonstrated meaningful biologic activity, acceptable safety and adequate dose-dependent persistence.
- Whether the MusCAARTes trial was initiated on schedule and whether patient enrollment and manufacturing capacity remain adequate.
- The company’s actual cash burn, investment balances and runway relative to the stated third-quarter 2023 estimate.
- The timing, size and dilutionary impact of future financing, given the absence of product revenue and the need for substantial additional capital.
- Progress and comparability of manufacturing technology transfer from Penn to Oxford Biomedica, WuXi or other contract manufacturers.
- The status, potential exposure and insurance coverage associated with the securities class action litigation.
- Continuing reliance on Penn, the status of the Penn license and sponsored research commitments, and any related milestone or royalty obligations.
- Whether clinical, regulatory, COVID-19 or supply-chain developments have materially changed the company’s stated timelines or risk profile.